NEW USE OF N,N-BIS-2-MERCAPTOETHYL ISOPHTHALAMIDE

(19)

(11)

EP 3 125 876 B8

(12)	CORRECTED EUROPEAN PATENT SPECIFICATION
	Note: Bibliography reflects the latest situation

(15)	Correction information:
	Corrected version no 1 (W1 B1)

(48)	Corrigendum issued on:
	24.01.2018 Bulletin 2018/04

(45)	Mention of the grant of the patent:
	29.11.2017 Bulletin 2017/48

(21)	Application number: 15723546.6

(22)	Date of filing: 31.03.2015

(51)

International Patent Classification (IPC):

A61K 31/166^(2006.01)

A61P 31/00^(2006.01)

(86)	International application number:
	PCT/GB2015/050999

(87)	International publication number:
	WO 2015/150793 (08.10.2015 Gazette 2015/40)

(54)	NEW USE OF N,N-BIS-2-MERCAPTOETHYL ISOPHTHALAMIDE NEUE VERWENDUNG VON N, N-BIS-2-MERCAPTOETHYL-ISOPHTHALAMID NOUVELLE UTILISATION DU N,N-BIS-2-MERCAPTOÉTHYL ISOPHTALAMIDE

(84)	Designated Contracting States:
	AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
	Designated Extension States:
	BA ME
	Designated Validation States:
	MA

(30)

Priority:

04.04.2014 GB 201406115

(43)	Date of publication of application:
	08.02.2017 Bulletin 2017/06

(73)	Proprietor: EmeraMed Limited
	Dublin 6 (IE)

(72)	Inventors:
	HALEY, Boyd Eugene Nicholasville, Kentucky 40356 (US) KLINGBERG, Ragnar Axel Theodor S-115 35 Stockholm (SE)

(74)	Representative: Potter Clarkson LLP
	The Belgrave Centre Talbot Street Nottingham NG1 5GG Nottingham NG1 5GG (GB)

(56)

References cited: :

US-A1- 2010 227 812

RISHI B. PATEL ET AL: "Thiol-redox antioxidants protect against lung vascular endothelial cytoskeletal alterations caused by pulmonary fibrosis inducer, bleomycin: comparison between classical thiol-protectant, N -acetyl-l-cysteine, and novel thiol antioxidant, N,N' -bis-2-mercaptoethyl isophthalamide", TOXICOLOGY MECHANISMS AND METHODS, vol. 22, no. 5, 1 June 2012 (2012-06-01), pages 383-396, XP055199056, ISSN: 1537-6516, DOI: 10.3109/15376516.2012.673089 cited in the application
RAHMAN IRFAN: "Antioxidant therapeutic advances in COPD", THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE, SAGE PUBLICATIONS LTD, UK, vol. 2, no. 6, 1 December 2008 (2008-12-01), pages 351-374, XP008171192, ISSN: 1753-4658, DOI: 10.1177/1753465808098224


	Remarks:
	The file contains technical information submitted after the application was filed and not included in this specification

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).